JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Cell lines
Isolated rat caudal artery, canine basilar, carotid, coronary and gastrosplenic arteries, and canine gastrosplenic and saphenous veins
Reaction Conditions
30 min incubation
Applications
Ketanserin dose-dependently inhibited contractile responses to 5-hydroxytryptamine (5-HT) in isolated rat caudal artery, canine basilar, carotid, coronary and gastrosplenic arteries, and canine gastrosplenic (threshold 10-10 ~ 10-9 M) and saphenous veins (threshold 10-8 M).
Animal models
Spontaneously hypertensive rats, 180 ~ 240 g
Dosage form
10 mg/kg/d
Administered orally for 5 months
Ketanserin significantly decreased blood pressure and blood pressure variability, ameliorated impaired arterial baroreflex function, and significantly prevented the target organs of spontaneously hypertensive rats from being damaged.
Note
The technical data provided above is for reference only.
References:
1. Van Nueten JM, Janssen PA, Van Beek J, et al. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. Journal of Pharmacology and Experimental Therapeutics, 1981, 218(1): 217-230.
2. Du WM, Miao CY, Liu JG, et al. Effects of long-term treatment with ketanserin on blood pressure variability and end-organ damage in spontaneously hypertensive rats. Journal of Cardiovascular Pharmacology, 2003, 41(2): 233-239.